Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme- Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice

Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.585
https://www.valueinhealthjournal.com/article/S1098-3015(13)02490-X/fulltext
Section Title : Disease-Specific Studies
Section Order : 565
First Page : A425
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02490-X&doi=10.1016/j.jval.2013.08.585
HEOR Topics :
Tags :
Regions :